Insulin secretion from pancreatic b cells is stimulated by glucagon-like peptide-1 (GLP-1), a blood glucose-lowering hormone that is released from enteroendocrine L cells of the distal intestine after the ingestion of a meal. GLP-1 mimetics (e.g., Byetta) and GLP-1 analogs (e.g., Victoza) activate the b cell GLP-1 receptor (GLP-1R), and these compounds stimulate insulin secretion while also lowering levels of blood glucose in patients diagnosed with type 2 diabetes mellitus (T2DM). An additional option for the treatment of T2DM involves the administration of dipeptidyl peptidase-IV (DPP-IV) inhibitors (e.g., Januvia, Galvus). These compounds slow metabolic degradation of intestinally released GLP-1, thereby raising post-prandial levels of circulating GLP-1 substantially. Investigational compounds that stimulate GLP-1 secretion also exist, and in this regard a noteworthy advance is the demonstration that small molecule GPR119 agonists (e.g., AR231453) stimulate L cell GLP-1 secretion while also directly stimulating b cell insulin release. In this review, we summarize what is currently known concerning the signal transduction properties of the b cell GLP-1R as they relate to insulin secretion. Emphasized are the cyclic AMP, protein kinase A, and Epac2-mediated actions of GLP-1 to regulate ATP-sensitive K þ channels, voltage-dependent K þ channels, TRPM2 cation channels, intracellular Ca 2þ release channels, and Ca 2þ -dependent exocytosis. We also discuss new evidence that provides a conceptual framework with which to understand why GLP-1R agonists are less likely to induce hypoglycemia when they are administered for the treatment of T2DM.
5.1.
Evidence that GLP-1 facilitates Ca 1. Blood glucose control by incretin hormone GLP-1
Enteroendocrine cells situated in the wall of the intestine act as nutrient sensors, and they release two "incretin hormones" in response to a meal. These hormones are glucagon-like peptide-1 (GLP-1) secreted by L cells, and glucose-dependent insulinotropic peptide (GIP) secreted by K cells. Since the administration of GLP-1 (but not GIP) to patients with type 2 diabetes mellitus (T2DM) results in a reduction of blood glucose concentration, one focus of current drug discovery efforts concerns the identification of small molecule compounds that will replicate the action of GLP-1, and that will reverse the chronic hyperglycemia that is characteristic of T2DM. In this regard, the Class II GTP-binding protein-coupled receptor for glucagon-like peptide-1 (designated as the GLP-1R) is an established target for blood glucose-lowering agents that are insulin secretagogues, and that are now in use for the treatment of T2DM (Ahren, 2009; Lovshin and Drucker, 2009; Nauck, 2011) .
The term "incretin effect" refers to the capacity of intestinally released GLP-1 and GIP to exert glucoregulatory effects in which they potentiate the action of orally administered glucose to stimulate pancreatic insulin secretion. These insulin secretagogue actions of GLP-1 and GIP lead to an insulin-dependent reduction of blood glucose levels, and the magnitude of this reduction is greater than what would be measurable if insulin secretion was instead stimulated by intravenous administration of glucose in the absence of intestinally released GLP-1 or GIP (Kieffer and Habener, 1999) .
The incretin effect is prominent in healthy individuals, whereas it is reduced in patients with T2DM. However, pharmacological doses of intravenously administered GLP-1 exert an acute stimulatory action to raise levels of plasma insulin, thereby lowering levels of blood glucose in patients with T2DM. Of major clinical significance is the fact that the insulin secretagogue action of GLP-1 at the b cell is glucose-dependent. In fact, GLP-1 is an effective insulin secretagogue only under conditions in which the blood glucose concentration is elevated, as is the case in T2DM. This property of GLP-1 is explained by the fact that under conditions in which the blood glucose concentration is hypoglycemic, GSIS is not initiated, and GLP-1 is therefore incapable of potentiating GSIS. What this means is that the acute insulin secretagogue and blood glucose-lowering actions of GLP-1 are self-terminating as blood glucose levels fall, and for this reason, hypoglycemia is less likely to occur when GLP-1 is administered to patients with T2DM. These properties of GLP-1 contrast with the glucose-independent insulin secretagogue actions of sulfonylureas such as tolbutamide. Sulfonylureas do not exert a self-terminating action to stimulate insulin secretion, and for this reason their use involves a risk for hypoglycemia (Knop et al., 2008) .
Studies of mice demonstrate that in addition to its insulin secretagogue action, GLP-1 acts as a b cell growth factor to stimulate insulin gene expression and insulin biosynthesis .
These studies also demonstrate that GLP-1 stimulates b cell proliferation (mitosis) while slowing b cell death (apoptosis) . Although it remains to be demonstrated that such actions of GLP-1 occur in humans, these findings suggest that longterm administration of a GLP-1R agonist might result in a beneficial increase of b cell mass and islet insulin content. The expected outcome would be an increased pancreatic insulin secretory capacity in T2DM patients administered GLP-1R agonists. Such beneficial antidiabetogenic properties are not characteristic of sulfonylureas.
It is also important to recognize that glucoregulation under the control of GLP-1 results not simply from its direct action at pancreatic b cells. Administered GLP-1R analogs act at pancreatic a cells to inhibit glucagon secretion, and this effect is accompanied by a suppression of hepatic glucose production (Hare et al., 2010) . Extra-pancreatic actions of GLP-1 lead to a slowing of gastric emptying, a suppression of appetite, and improved cardiovascular performance . Such actions of GLP-1 are likely to be mediated not only by its Class II GPCR, but also by a nonconventional pathway activated by metabolites of GLP-1 designated as GLP-1(9e36-amide) (Tomas and Habener, 2010) or GLP-1(28e36-amide) (Tomas et al., 2011) . Indeed, speculation has centered on whether this as-yet-to-be identified non-conventional pathway allows GLP-1 to exert an "insulin mimetic" action at the liver. It is presently unclear which GLP-1R analogs now in use for the treatment of T2DM have the capacity to exert effects mediated by this non-conventional pathway, and furthermore, it is uncertain whether inhibitors of GLP-1 metabolism exert undesirable side effects as a consequence of their ability to prevent the formation of GLP-1(9e36-amide) and GLP-1(28e36-amide). Therefore, opportunity exists to expand on our present understanding of GLP-1 pharmacology and physiology.
GLP-1-based therapies for the treatment of type 2 diabetes
One GLP-1-based strategy for the treatment of T2DM involves the subcutaneous administration of GLP-1R agonists such as Byetta (exenatide; a synthetic form of exendin-4) or Victoza (liraglutide), a modified form of GLP-1. Unlike GLP-1, both Byetta and Victoza are resistant to metabolic degradation catalyzed by dipeptidyl peptidase-IV (DPP-IV), and for this reason these compounds exert prolonged insulin secretagogue actions when they are administered subcutaneously. This is significant because the hydrolytic activity of DPP-IV quickly renders endogenous GLP-1 inactive, thereby making it an unsuitable treatment for T2DM (Holst, 2004; Israili, 2009) .
A second GLP-1-based strategy for the treatment of T2DM involves the administration of DPP-IV inhibitors, compounds that have an ability to raise levels of circulating GLP-1, while having no direct stimulatory effect on L cell GLP-1 secretion. Mechanistically, DPP-IV inhibitors prevent the conversion of GLP-1(7e36-amide) to GLP-1(9e36-amide). Such compounds include Januvia (sitagliptin) and Galvus (vildagliptin), both of which are now in use for the treatment of T2DM. As alluded to above, GLP-1(9e36-amide) may have important actions mediated by a non-conventional pathway, and for this reason it could be that the actions of GLP-1(9e36-amide) would be absent in T2DM patients administered DPP-IV inhibitors. Despite this uncertainty, DPP-IV inhibitors are an attractive therapeutic option due to the fact that these small molecule compounds can be administered orally (Israili, 2009) .
There also appears to be great potential for the development of small molecule compounds that stimulate GLP-1 secretion. In this regard, the best-characterized compounds are designated as GPR119 agonists. GPR119 is a Class I GPCR expressed on L cells, and it mediates stimulatory effects of fatty acid-amides on GLP-1 secretion.
Since GPR119 is also expressed on b cells, a GPR119 agonist such as AR231453 exerts multiple effects when it is administered orally in combination with glucose (Chu et al., 2008 (Chu et al., , 2007 . It stimulates L cell GLP-1 secretion, thereby allowing circulating GLP-1 to bind to the b cell GLP-1R and to stimulate insulin secretion. Simultaneously, it directly stimulates insulin secretion by activating GPR119 that is co-expressed with the GLP-1R on b cells. Available evidence indicates that GPR119 agonists exert these secretagogue actions by stimulating cAMP production in the L cells and b cells. The attractiveness of GPR119 agonists is further enhanced by the fact that they are also orally administrable (Jones et al., 2009; Shah and Kowalski, 2010) .
3. GLP-1R activation enhances K ATP channel closure and depolarizes b cells Since GLP-1 stimulates cAMP production in pancreatic b cells (Fig. 1) , and because insulin secretion is stimulated by cAMPelevating agents such as forskolin, there is good reason to believe that the b cell GLP-1R is coupled to cAMP production and insulin exocytosis. Such effects of GLP-1 are likely to be mediated by protein kinase A (PKA) and the Rap GTPase guanine nucleotide exchange factor known as Epac2 (Fig. 1) (Holz, 2004a) . In view of the fact that GLP-1 fails to stimulate insulin secretion in the absence of glucose, and since insulin secretion stimulated by glucose does not necessarily require co-administration of GLP-1, it is widely accepted that the physiologically relevant role of GLP-1 is to potentiate GSIS.
In this "consensus model" of b cell stimulus-secretion coupling, b cell glucose metabolism is deemed to be the primary stimulus for insulin secretion, whereas cAMP metabolism is viewed as a potentiating factor, one that is capable of interacting with, and possibly modulating, glucose metabolism (Holz, 2004b) . Interestingly, GLP-1 is reported to restore the glucose sensitivity of rat b cells that have been rendered metabolically compromised after their exposure to a glucose-free solution (Holz et al., 1993) . This induction of "glucose competence" by GLP-1 might be of therapeutic significance since it suggests a capacity of GLP-1 to act through cAMP in order to repair metabolically compromised b cells in the islets of patients with T2DM (Holz and Habener, 1992) .
Consistent with the above-summarized concepts, pancreatic insulin secretion is initiated following a simultaneous rise in blood Holz et al., 1993) , and this modulatory action of GLP-1 appears to involve not only PKA (Light et al., 2002) , but also Epac2, a novel cAMP-binding protein that interacts directly with nucleotide binding-fold 1 (NBF-1) of the sulfonylurea receptor 1 (SUR1) subunit of K ATP channels (Kang et al., , 2008 Ozaki et al., 2000; Shibasaki et al., 2004b) . A role for PKA and Epac2 in the control of K ATP channels is indicated because the inhibitory action of GLP-1 at K ATP channels is mimicked by the catalytic subunit of PKA (Light et al., 2002) , and also by 8-pCPT-2 0 -O-Me-cAMP, an Epac-selective cAMP analog (ESCA) that does not activate PKA when it is used at appropriately low concentrations (Enserink et al., 2002; Holz et al., 2008a ). In our most recent studies, we find that K ATP channel inhibition by ESCAs can best be evaluated using a new and improved cAMP analog (8-pCPT-2 0 -O-Me-cAMP-AM) that is modified to incorporate an acetoxymethyl ester (AM-ester) moiety, thereby rendering it highly membrane permeable Vliem et al., 2008) . In side-by-side comparisons examining the actions of GLP-1R agonist exendin-4 (Ex-4) and the newly available ESCA-AM, we find that both substances depolarize mouse b cells, as studied in intact islets (Fig. 2AeC) , or in single b cells (Fig. 3A,B) . These depolarizing actions of Ex-4 and the ESCA-AM are accompanied by an increase of [Ca 2þ ] i that in intact islets is sometimes accompanied by synchronous oscillations of the membrane potential and [Ca 2þ ] i (Fig. 2C) . Importantly, all such actions of Ex-4 and the ESCA-AM can be measured under conditions in which islets or b cells are treated with the PKA inhibitor H-89 (Figs. 2AeC, 3A,B) . Furthermore, such actions of Ex-4 and the ESCA-AM require that islets and b cells be equilibrated in a concentration of glucose that is stimulatory for insulin secretion, as expected if b cell glucose metabolism and Epac2 activation interact synergistically to close K ATP channels and to depolarize b cells.
To provide additional confirmation that the depolarizing action of the ESCA-AM results from the closure of K ATP channels, our studies included measurements of the whole-cell K ATP current and single K ATP channel activity in mouse b cells since such an analysis has not been reported for mice. We find that the hydrolysis-resistant Epac activator Sp-8-pCPT-2 0 -O-Me-cAMPS reduces a glyburide-sensitive membrane current that corresponds to the whole-cell K ATP current (Fig. 3C,D) . We also find that the Epac activator 2 0 -O-Me-cAMP inhibits the activity of single K ATP channels, as measured in insideout excised patches (Fig. 3E,F 
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Active Fig (PKA) and Epac2, although islets are also known to express low levels of Epac1 Kelley et al., 2009 ). The regulatory subunits of PKA contain a dimerization domain (D), a pseudosubstrate domain (j), and two cyclic nucleotide binding domains (CNBD, A & B) where cAMP binds and causes the dissociation and activation of the catalytic (Cat.) subunits. In the absence of cAMP, CNBD-A of the regulatory subunit plays an important role in binding the catalytic subunit, whereas CNBD-B reduces the K a for activation of PKA by cAMP (Sjoberg et al., 2010) . The regulatory subunits also bind A-kinase anchoring proteins (AKAPs) that play an important role in the cellular localization of PKA that is under the control of GLP-1 (Lester et al., 1997) . The N-terminal of Epac2 contains two CNBDs (A & B) separated by a DEP domain (Disheveled, Egl-10, Pleckstrin homology domain). This is the regulatory region (Reg.) of Epac2, and it sterically inhibits the C-terminal catalytic region (Cat.). Two interaction zones are formed in the inactive state of Epac2, an ionic latch (IL, red) and a switch board (SB, green).
Binding of cAMP to CNBD-B causes a conformational change that allows Rap to bind the CDC25 homology domain that catalyzes GTP/GDP exchange and activation of Rap. The catalytic domain of Epac2 also contains a Ras-exchanger motif (REM) and a Rasassociation domain (RA). In these prior studies, Epac2 activation produced a left-shift in the doseeresponse relationship describing ATP-induced inhibition of K ATP channels (Kang et al., 2008) . Thus, our findings are consistent with the view that GLP-1 potentiates the inhibitory action of b cell glucose metabolism at K ATP channels, thereby explaining why the insulin secretagogue action of GLP-1 is glucose-dependent. Interestingly, Epac2 activation also increases the inhibitory effect of sulfonylureas at K ATP channels. This finding may explain the increased incidence of hypoglycemia that is observed in humans when sulfonylureas are administered in combination with GLP-1R agonists . To explain prior observations concerning K ATP channel regulation, we proposed a model whereby Epac2 activation leads to Rap1 GTPase activation, thereby allowing Rap1 to activate its cognate effector phospholipase C-epsilon (PLC 3) . Since Epac2 is bound to SUR1, this leads to the hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP 2 ) in the immediate vicinity of K ATP channels. By removing the activating effect of PIP 2 at K ATP channels, the open probability of K ATP channels is reduced, thereby leading to an increased apparent affinity of the channels for ATP and sulfonylureas. The net effect is an increased ability of ATP and sulfonylureas to inhibit K ATP channels. This model incorporates the concept that SUR1 serves as scaffold at which is located a signaling complex comprised of Epac2, Rap1, and PLC 3.
An alternative model, based on studies of vascular smooth muscle, proposes that Epac activation leads to the stimulation of protein phosphatase 2B (PP2B/calcineurin), with consequent dephosphorylation and inhibition of K ATP channels (Purves et al., 2009) . Such findings are noteworthy since calcineurin inhibitors are used as immunosuppressants after organ transplantation. Since calcineurin inhibitors inhibit insulin secretion and predispose to diabetes (Ozbay et al., 2011) , it is possible that their clinical use as immunosuppressants explains the development of posttransplantation diabetes. In this scenario, calcineurin inhibitors antagonize an Epac2-mediated inhibitory effect of GLP-1 at K ATP channels, thereby upregulating channel activity so that glucose metabolism is a less effective stimulus for K ATP channel closure and insulin secretion.
Since Epac2 binds to SUR1, and since this interaction is disrupted by cAMP (Shibasaki et al., 2004a) , it is conceivable that Epac2 exerts a direct effect at K ATP channels, and that this effect is independent of Rap1, PLC 3, or calcineurin. It is also possible that the interaction of Epac2 with SUR1 enables the formation of a signaling complex that directly controls exocytosis. Such a concept is consistent with the finding that Epac2 binds to Munc13-1 (Kwan et al., 2007) , a protein that is important for ATP-dependent "priming" and exocytosis of secretory granules and synaptic vesicles in excitable cells (Sheu et al., 2003) . Exocytosis under the control of Munc13-1 is enhanced by the production of endogenous diacylglycerol (DAG) (Sheu et al., 2003) . Thus, it is possible that the activation of Epac2 bound to SUR1 results in PLC 3 activation, with consequent generation of DAG from its precursor PIP 2 . In this model, PIP 2 hydrolysis promotes K ATP channel closure and Ca 2þ influx, while also providing the DAG that activates Munc13-1. Simultaneously, DAG may activate protein kinase C (PKC), thereby additionally facilitating insulin exocytosis, possibly by increasing the size of a highly Ca 2þ -sensitive pool of secretory granules (Wan et al., 2004; Yang and Gillis, 2004) .
GLP-1 inhibits voltage-dependent K D currents in b cells
Evidence exists that the GLP-1R agonist Ex-4 acts through PKA to inhibit a voltage-dependent K þ current in rat b cells (MacDonald et al., 2002) . This effect of Ex-4 is one that should enhance GSIS since the inhibition of voltage-dependent K þ channels (K V ) leads to action potential prolongation, thereby allowing increased Ca 2þ influx during each action potential. Given that GLP-1 has only a small facilitatory effect on voltage-dependent Ca 2þ currents in b cells (Gromada et al., 1998) , any action of GLP-1 to inhibit K V channels might be of considerable significance. Interestingly, the PKA-mediated action of Ex-4 to inhibit K V channels in rat b cells is reinforced by a cAMP-independent action of the peptide to signal through the GLP-1R and to activate PI3-kinase (MacDonald et al., 2003) . This PI3-kinase-mediated signaling capacity of the GLP-1R is attributed to its ability to promote epidermal growth factor receptor (EGF-R) "transactivation" with consequent activation of b cell growth factor-like signaling pathways (Buteau et al., 2003) . . Perforated patch (top trace) measurements of the membrane potential (Vm) were obtained from a cell located on the surface of a mouse islet. Simultaneously, the whole-islet [Ca 2þ ] i was measured using fura-2 (lower trace). A small bolus of test solution containing 10 nM exendin-4 (Ex-4, horizontal bar) was applied directly to the islet, and it stimulated depolarization and an increase of [Ca 2þ ] i . Note that in this experiment, a train of action potentials was superimposed on a plateau depolarization (for methods, see (Holz et al., 1995) ).
B). Depolarization (top trace) accompanied by an increase of whole-islet [Ca 2þ ] i (lower trace) was also measured when a mouse islet was exposed to 1 mM 8-pCPT-2 0 -O-Me-cAMP-AM (ESCA-AM). The initial burst of action potentials is shown on an expanded time scale in the inset (b 1 ). For A and B, the bath solution contained 7.5 mM glucose and 10 mM H-89, thereby establishing that PKA activity was not required to induce depolarization. C). Perforated patch measurements of Vm (top trace) and whole-islet Since activation of the EGF-R results in Ras GTPase activation that directly activates PLC 3, it could be that a convergent mechanism of GLP-1R signal transduction exists in which PLC 3 catalyzed hydrolysis of PIP 2 underlies inhibitory effects of GLP-1 at K ATP and K V channels. The whole-cell K ATP current of a mouse b cell was measured under conditions of voltage clamp and dialysis using 0.3 mM ATP (for methods, see ). This K ATP current was inhibited by Sp-8-pCPT-2 0 -O-Me-cAMPS (100 mM) (C) or glyburide (Glyb., 10 nM) (D) applied extracellularly (horizontal bars). Findings are representative of results obtained using n ¼ 6 b cells from two C57BL/6 mice per experimental condition. E). Single K ATP channel activity was measured in excised inside-out patches from mouse b cells (for methods, see (Kang et al., 2008) ). Application of ATP (10 mM) to the intracellular surface of the patch inhibited K ATP channel activity. Subsequent application of the Epac activator 2 0 -O-MecAMP (ESCA; 10 or 50 mM) further inhibited channel activity. F). The actions of ATP and 2 0 -O-Me-cAMP measured in excised patches were quantified as NP o values of K ATP channel activity normalized to the K ATP channel activity measured at the start of the experiment in the absence of ATP and 2 0 -O-Me-cAMP (for methods, see (Kang et al., 2008) ). Results for F are the means þ s.e.m. using three excised patches from three b cells of three C57BL/6 mice.
Evidence that GLP-1 facilitates Ca
2þ -induced Ca 2þ release GLP-1 facilitates CICR in mouse and human b cells, and also in rat INS-1 cells that secrete insulin (Holz et al., 1999; Kang et al., 2001 ). This CICR is generated by the opening of intracellular Ca 2þ release channels, the various subtypes of which are expressed in a speciesspecific manner such that the expression of the type-2 isoform of RYR (RYR-2) is higher in human and rat b cells, whereas it is lower in mouse b cells that may instead primarily use the IP 3 R to mobilize Ca 2þ (Beauvois et al., 2004; Dyachok and Gylfe, 2004; Dyachok et al., 2004; Holz et al., 1999) . For human and mouse b cells, CICR can be facilitated not only by GLP-1, but also by cAMP analogs that activate either PKA or Epac2 selectively. This finding demonstrates that there is dual PKA and Epac2 regulation of the Ca 2þ release process (Kang et al., 2005 . In fact, it has been proposed that b cell IP 3
receptors are under the control of PKA, whereas RYR-2 is under the control of Epac2 (Gromada et al., 2004; Tsuboi et al., 2003) . ] and [cAMP] , and these oscillations are coupled to exocytosis of insulin (Dyachok et al., 2008; Holz et al., 2008b; Landa et al., 2005) .
Available evidence indicates that Ca 2þ influx through L-type (nifedipine-sensitive) VDCCs results in an increase of cytosolic Ca 2þ concentration that serves as a trigger for CICR if and only if the intracellular Ca 2þ release channels are in a sensitized state (Gromada et al.,1995 (Gromada et al., , 2004 Holz et al.,1999) . PKA-dependent facilitation of CICR by GLP-1 is believed to be a consequence of the phosphorylation of intracellular Ca 2þ release channels Holz et al., 1999) . Simultaneously, PKA may synergize with b cell glucose metabolism to promote the uptake of Ca 2þ into intracellular organelles, thereby increasing the amount of Ca 2þ available for release (Yaekura and Yada, 1998 " that is bound to NP-EGTA (Fig. 4) ] i that is measured simply reflects the uncaging of Ca 2þ (Fig. 4A) . However, if the experiment is repeated under conditions in which the uncaging of Ca 2þ is paired with the application of 8-pCPT-2 0 -O-Me-cAMP-AM to a b cell, then CICR is generated (Fig. 4A) . A similar facilitation of CICR is measured in response to Ex-4 or the PKA-selective cAMP analog Db-cAMP-AM (Fig. 4B,C) . By repeating this assay using b cells from Epac2 or PLC 3 knockout (KO) mice, it is possible to demonstrate that the KO of Epac2 or PLC 3 nearly abrogates the facilitatory action of 8-pCPT-2 0 -O-Me-cAMP-AM, while not affecting the action of Db-cAMP-AM (Fig. 4B,C) . Furthermore, as expected for a GLP-1R agonist that activates both PKA and Epac2, these same two knockouts reduce, but do not abrogate, the facilitatory action of Ex-4 (Fig. 4B,C) ] by equivalent amounts when comparing its actions in wild-type or Epac2 and PLC 3 KO mouse b cells . Based on these summarized data, it may be concluded that in b cells there exists a mechanism of second messenger coincidence detection in which intracellular Ca 2þ release channels respond to Ca 2þ and cAMP generated as a consequence of GLP-1R stimulation (Kang et al., 2005) . Future efforts will be directed at establishing whether these Ca 2þ release channels correspond to the IP 3 R, RYR, or NAADPR. (Fig. 5A) . Surprisingly, this action of Ex-4 in HEK-GLP-1R cells is not blocked by inhibitors of PKA (H-89, Rp-8-CPT-cAMPS), nor is it antagonized by ryanodine (Fig. 5B) . Moreover, this action of Ex-4 is mimicked by the cAMP-elevating agents forskolin and IBMX, and these actions are measurable under conditions in which cells are virally transduced with a dominant-negative Epac2 (Fig. 5D) . Thus, it seems that neither PKA activation nor Epac2 activation can explain how Ex-4 exerts its action in this assay. Such a conclusion is reinforced by the finding that 8-pCPT-2 0 -O-Me-cAMP-AM has little capacity to potentiate the Ca 2þ mobilizing action of ADP (Fig. 5C ).
Since a selective blocker of PLC (U73122) . HEK293 cells were virally transduced with wild-type (wt) or dominant-negative (dn) Epac2 (for details regarding wt and dn Epac2, see (Kang et al., 2001) ). A 2-step injection protocol was used so that in the first injection the solution contained either: 1) 0.1% DMS0 vehicle (Veh), or 2) 2 mM forskolin and 50 mM IBMX (F/I), or 3) 10 pM exendin-4 (Ex-4), or 4) 3 mM 8-pCPT-2 0 -O-Me-cAMP-AM (ESCA). 60 s after the first injection, a second injection was performed in which ADP (10 nM) was administered. D). Potentiation of ADP (10 nM) induced Ca 2þ mobilization by forskolin and IBMX (F/I) was unaffected by pretreatment of HEK293 cells with PKA inhibitor H-89 (5 mM), the CaMK-II inhibitor KN-93 or its inactive analog KN-92 (1 mM, each) , or the MEK inhibitors (PD98059 (25 mM) and U0126 (10 mM). Only the PLC inhibitor U73122 (2 mM) was an effective antagonist in this assay.
structurally-related to the GLP-1R. In those published studies, it was concluded that cAMP exerts a direct action at the IP 3 R to facilitate its opening, and that this action of cAMP is independent of both PKA and Epac (Tovey et al., 2010) . Taken together, these observations raise the possibility that a non-conventional mechanism of Ca 2þ mobilization underlies the ability of GLP-1 to facilitate the release of Ca 2þ from IP 3 R-regulated Ca 2þ stores in b cells.
Potential NAADP receptor-mediated actions of GLP-1
NAADP is a Ca 2þ -mobilizing metabolite that is reported to bind to and stimulate the opening of "two-pore" Ca 2þ channels (TPCs) (Calcraft et al., 2009; Naylor et al., 2009) . These TPCs mediate the mobilization of Ca 2þ from "acidic Ca 2þ stores" (Fig. 6A) , and this source of Ca 2þ may be localized in the lysosomes, endosomes, and possibly secretory granules . Evidence also exists that the mobilization of Ca 2þ from these stores might enhance b cell electrical excitability and insulin secretion due to stimulatory effects of released Ca 2þ on plasma membrane cation channels . Thus, it is of interest that GLP-1 is reported to act through PKA and Epac2 to mobilize Ca 2þ that is stored within the acidic Ca 2þ stores of b cells (Kim et al., 2008) .
One way acidic Ca 2þ stores are operationally defined is that they are emptied following treatment with bafilomycin. This inhibitor of the vacuolar-type H þ -ATPase is responsible for proton transport that acidifies the intra-organellar compartment, thereby enabling sequestration of Ca 2þ . We have evaluated the potential role of acidic Ca 2þ stores in the mobilization of Ca 2þ by cAMP, and in this regard we find that treatment of mouse b cells with bafilomycin fails to disrupt the action of 8-pCPT-2 0 -O-Me-cAMP-AM to facilitate CICR under conditions of NP-EGTA loading and UV flash photolysis . In marked contrast, the facilitatory action of 8-pCPT-2 0 -O-Me-cAMP-AM is blocked by thapsigargin, an inhibitor of SERCA ATPases that mediate the uptake of Ca 2þ into the ER of b cells. Importantly, we also find that thapsigargin disrupts the action of a PKA-selective cAMP analog (6-Bnz-cAMP-AM) to facilitate CICR . Therefore, available evidence indicates that it is the ER from which Ca 2þ is released under the experimental conditions used in our assay of CICR. This conclusion is reinforced by our prior finding that in mouse b cells, the ability of forskolin to facilitate CICR is antagonized by heparin, an inhibitor of IP 3 R dependent ER Ca 2þ release (Kang et al., 2005) . , and inhibited by adenine nucleotides (Sturgess et al., 1986) . They were later found to be regulated by cyclic nucleotides (Reale et al., 1995) . Subsequently, GLP-1 was shown to activate a nonselective cation current in b cells (Holz et al., 1995) . This current appears to be identical to the current activated by maitotoxin (Leech and Habener, 1998) , and it is generated by the opening of CAN channels that have a single channel conductance of 25e30 pS (Leech and Habener, 1998) . The properties of these CAN channels resemble those of TRPM4 channels, a class of CAN channels that play a role in glucose-stimulated and arginine-vasopressin-regulated insulin secretion (Cheng et al., 2007; Marigo et al., 2009 ). In addition to TRPM4, the closely related CAN channel TRPM5 also plays a role in glucose-stimulated insulin secretion (Brixel et al., 2010; Colsoul et al., 2010) . Thus, an attractive hypothesis is that TRPM4 and/or TRPM5 might be under the control of GLP-1, and that activation of these channels would lead to membrane depolarization, Na þ and Ca 2þ influx, and increased b cell excitability.
TRPM2 is also a non-selective cation channel, and it is activated by heat and ADP-ribose in b cells. Its activation may explain some stimulatory effects of glucose and GLP-1 on insulin secretion. In this regard, cyclic-ADP-ribose may mediate these effects (Lange et al., 2009; Togashi et al., 2006; Uchida et al., 2011) . Evidence also exists that TRPM2 participates in cell death initiated by reactive oxygen species-induced release of Ca 2þ from lysosomes (Lange et al., 2009 ). Finally, it should be noted that TRPV1 and TRPV2 are expressed in b cells, and that these capsaicin-activatable channels seem to play some role in the dual control of insulin secretion and b cell growth (Akiba et al., 2004) . Thus, it will be particularly interesting to assess whether any of these Trp channel variants are under the control of GLP-1.
7. GLP-1 exerts a direct stimulatory effect on Ca
2D
-dependent exocytosis GLP-1 also exerts a direct action at "late steps" of b cell stimulussecretion coupling in order to facilitate Ca 2þ -dependent exocytosis of insulin. This capacity is understandable because PKA activity increases the size of a highly Ca 2þ -sensitive pool (HCSP) of secretory granules in b cells (Wan et al., 2004; Yang and Gillis, 2004) .
Conceivably, this action of PKA may allow CICR to efficiently trigger insulin exocytosis . Since PKC activity also increases the size of the HCSP (Wan et al., 2004; Yang and Gillis, 2004) , and since GLP-1 acts through PLC to activate PKC Suzuki et al., 2006) , it seems likely that the dual regulation of the HCSP by PKA and PKC underlies some stimulatory effects of GLP-1 on insulin secretion. Given that the HCSP is not prepositioned adjacent to VDCCs at the plasma membrane, this pool of secretory granules may undergo exocytosis in response to Ca 2þ released from intracellular organelles.
Evidence also exists that GLP-1 acts through PKA to recruit secretory granules from a reserve pool into a readily releasable pool (RRP) that is docked and primed in close proximity to VDCCs (Renstrom et al., 1997) . These secretory granules undergo exocytosis in response to high concentrations (10e20 mM) of Ca 2þ that form in microdomains at the inner mouths of VDCCs (Barg et al., 2002; Bokvist et al., 1995) . Thus, in the presence of GLP-1, and under conditions in which PKA is activated, Ca 2þ influx through VDCCs initiates exocytosis of the RRP. Simultaneously, exocytosis of the HCSP may be initiated by CICR that is itself triggered by Ca 2þ influx.
This concept is consistent with the observation that CICR generates a global increase of cytosolic [Ca 2þ ] that is comparatively small in magnitude (0.5e1.0 mM), but that may be capable of releasing the HCSP. One interesting prediction of this model is that in the absence of GLP-1, exocytosis stimulated by glucose metabolism will release a small number of secretory granules located within the RRP without stimulating exocytosis of the HCSP. However, in the presence of GLP-1, both the RRP and the HCSP undergo exocytosis, thereby suggesting that exocytosis initiated by CICR constitutes an amplification mechanism that enables GLP-1 to potentiate GSIS . A "post-priming" step in insulin exocytosis is also under the control of PKA, and it may mediate the action of GLP-1 to potentiate GSIS (Takahashi et al.,1999) . This finding is understandable if in b cells there exists PKA-mediated phosphorylation of soluble N-ethylmaleimidesensitive factor attachment protein receptor (SNARE) proteins, and their protein-interacting partners. Such proteins may include Snapin, a PKA substrate that interacts with the SNARE protein SNAP-25, and that regulates a direct association of the Ca 2þ -sensor synaptotagmin with the core SNARE complex (Chheda et al., 2001; Ilardi et al., 1999; Song et al., 2011) . More speculative is the potential role of PKA substrate Rim2. It is a SNAP-25 and Mun13-1 interacting protein that acts at an earlier step in exocytosis, one that supports the ATPdependent priming of secretory granules, a step that renders the granules release competent (Kwan et al., 2007) .
There is also substantial evidence that Epac2 participates in the regulation of exocytosis by GLP-1. For example, Epac2 interacts with Piccolo (a Ca 2þ -sensor), and Rim2 (a Rab3 effector), both of which play a role in exocytosis (Shibasaki et al., 2004a) . Moreover, the knockdown of Epac2 expression is reported to diminish GLP-1-stimulated insulin secretion by ca. 50% (Kashima et al., 2001) . In these assays, the action of GLP-1 mediated by Epac2 is also demonstrated to be mediated by Rim2 (Kashima et al., 2001) , and the importance of Rim2 to insulin exocytosis is now quite clear (Kwan et al., 2007; Yasuda et al., 2010) . Interestingly, the SNARE protein SNAP-25 also binds Epac2, and the formation of an Epac2, SNAP-25, and Rim2 complex may mediate additional stimulatory actions of GLP-1 on insulin exocytosis (Vikman et al., 2009) . Finally, it is important to note that Epac2 activation promotes secretory granule acidification, a step necessary for granule priming and release competence (Eliasson et al., 2003) . Since this action of Epac2 is absent in SUR1 knockout mice, it appears that cAMP-dependent granule acidification is contingent on the interaction of Epac2 with SUR1. This might explain why the insulin secretagogue action of GLP-1 is reduced in SUR1 knockout mice (Nakazaki et al., 2002; Shiota et al., 2002) .
Additional insights concerning the stimulatory action of GLP-1 on insulin secretion have been obtained in studies examining interactions of Ca 2þ channel subunits with SNARE-associated proteins. Both
Piccolo and Rim2 are reported to bind to the a1.2 subunit of L-type Ca 2þ channels in b cells (Shibasaki et al., 2004a) , and this interaction may anchor L-type Ca 2þ channels in lipid rafts to form a signaling complex important for glucose and GLP-1 regulated insulin secretion (Jacobo et al., 2009b) . The intracellular II-III loop of Ca V 1.2 immunoprecipitates with Rim2 (Jacobo et al., 2009b) , consistent with previous data showing that Rim2 specifically binds Ca V 1.2 through its C2 domain (Shibasaki et al., 2004a) . These findings correlate with the fact that that the knockdown of Ca V 1.2 expression in INS-1 cells disrupts GSIS (Nitert et al., 2008) . Studies performed with transfected INS-1 cells expressing dyhydropyridine-insensitive Ca 2þ channel mutants seem to indicate that GSIS under the control of GLP-1 also requires the expression of Ca V 1.3 (Liu et al., 2003) . This approach has revealed that influx of Ca 2þ through Ca V 1.3 stimulates exocytosis that can be potentiated by 8-pCPT-2 0 -O-Me-cAMP, and that this effect of the Epac activator requires permissive PKA activity since it is blocked by H-89 (Jacobo et al., 2009a; Liu et al., 2003) . Similarly, the insulin secretagogue action of 8-pCPT-2 0 -O-Me-cAMP-AM in human islets is blocked by Rp-8-CPT-cAMPS, an antagonist of PKA activation . Importantly, the PKA-dependent insulin secretagogue action of 8-pCPT-2 0 -O-Me-cAMP-AM is not explained by any unexpected action of this cAMP analog to activate PKA. This fact was demonstrated in assays of b cells expressing AKAR3, a biosensor that reports PKA activation . What remains unclear is the nature of the permissive PKA activity that supports insulin secretion. Available evidence suggests that permissive PKA activity might be the consequence of b cell glucose metabolism (Hatakeyama et al., 2006) .
Such findings lend credibility to the idea that PKA plays a critical role in support of insulin exocytosis that is under the dual control of glucose metabolism and GLP-1.
Current controversies regarding Epac2 and PKA
Despite direct evidence that GSIS can be potentiated by 8-pCPT-2 0 -O-Me-cAMP-AM , there exists controversy concerning the exact role Epac2 plays in the control of exocytosis. An important role for Epac2 is indicated since b cells of Epac2 KO mice exhibit a secretory defect in which the action of cAMP to potentiate first phase GSIS is reduced (Shibasaki et al., 2007) . What is surprising is that two-photon extracellular polartracer (TEP) imaging studies of b cells do not substantiate a role for Epac2 in the control of insulin secretion (Hatakeyama et al., 2007) . However, it is important to emphasize that these TEP studies were performed under conditions in which exocytosis was stimulated by the uncaging of Ca 2þ . Exocytosis studied in this manner is not representative of GSIS due to the fact that this approach bypasses early steps of stimulus-secretion coupling that involve K ATP channel closure. Since first phase GSIS is primarily a K ATP channel dependent mechanism of exocytosis (Henquin, 2000) , and since the KO of Epac2 disrupts first phase GSIS, it could be that under true physiological conditions, the primary role of Epac2 is to mediate cAMP-dependent closure of K ATP channels, thereby depolarizing b cells. This concept is consistent with the therapeutically important action of GLP-1 to restore the missing first phase component of GSIS in patients with T2DM. In this regard, it is noteworthy that the action of GLP-1 to potentiate GSIS is strongly attenuated in mice in which there is a knockout of the K ATP channel SUR1 or Kir6.2 subunits (Miki et al., 2005; Nakazaki et al., 2002; Shiota et al., 2002) . These findings are interpretable if an Epac2-mediated action of GLP-1 to close K ATP channels plays an important role in conferring stimulatory effects of GLP-1 on insulin secretion. This concept is further supported by studies of Kcnj11 Y12STOP mice in which the insulin secretagogue action of GLP-1 is reduced (Hugill et al., 2010) . In these mutant mice, the gene coding for Kir6.2 (Kcnj11) contains an inactivating tyrosine to stop codon point mutation (Y12STOP) so that K ATP channel activity is undetectable in islet b cells. Thus, in b cells with no active K ATP channels, the insulin secretagogue action of GLP-1 is nearly absent, thereby establishing K ATP channels to be critically important intermediaries linking GLP-1R activation to islet insulin secretion (Hugill et al., 2010) .
Summary
The remarkable effectiveness of incretin-based therapies for the treatment of T2DM has spurred continued efforts to pinpoint exactly how GLP-1 exerts its stimulatory effects at the b cell. In this regard, ongoing efforts are primarily devoted to understanding the differential, yet complementary roles, PKA and Epac2 play in the potentiation of GSIS. An outgrowth of recent studies is that it is increasingly appreciated that GLP-1 may act through PKA and Epac2 to modulate the ADP and ATP sensitivities of K þ channels (Light et al., 2002; Kang et al., 2008) . This action of GLP-1 may allow b cell glucose metabolism to more efficiently close these channels, thereby stimulating insulin secretion. To what extent GLP-1 has any capacity to enhance oxidative glucose metabolism in the b cell is a topic of considerable interest. However, discrepant findings concerning this possibility remain to be resolved (Peyot et al., 2009; Tsuboi et al., 2003) . In conclusion, the biochemical and molecular basis for beneficial insulin secretagogue and blood glucose-lowering actions of incretin mimetics, GLP-1R analogs, and DPP-IV inhibitors remains a topic of considerable interest to the diabetes research community.
